Page 1 of 6 123456 LastLast
Results 1 to 10 of 54

Thread: InVivo Update

  1. #1
    Senior Member JeffH's Avatar
    Join Date
    Jun 2006
    Location
    Bend, Oregon
    Posts
    651

    InVivo Update

    • "On May 14, 2015, InVivo Therapeutics put out an update on the two patients enrolled in the company's pilot study with its Neuro-Spinal Scaffolding device."

    http://seekingalpha.com/article/3183...invivos-update

    Jeff

  2. #2

  3. #3
    Wish they would try it on a chronic ASIA-A

  4. #4

  5. #5
    That's a hell of a meet cute.

  6. #6

  7. #7
    James Guest, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Guest is currently a Professor of Neurological Surgery at the Miller School of Medicine and the Miami Project to Cure Paralysis in Miami, FL."

    Link
    In God we trust; all others bring data. - Edwards Deming

  8. #8
    Likely evaluating whether this fits with their stem cells or Schwann cells. both in early trials.

    Quote Originally Posted by paolocipolla View Post
    James Guest, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Guest is currently a Professor of Neurological Surgery at the Miller School of Medicine and the Miami Project to Cure Paralysis in Miami, FL."

    Link

  9. #9
    CAMBRIDGE, Mass. (June 30, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Rutgers New Jersey Medical School in Newark, NJ has been added as a clinical site in the company’s ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Robert Heary, M.D., Professor of Neurological Surgery and Director of the Spine Center, has been named Principal Investigator at this site.

    Is this the start of collaboration?
    please . . .test what you already know; and give us what you have. we may not be dying, but we certainly are not living either

  10. #10
    http://www.invivotherapeutics.com/pr...inal-scaffold/

    InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold

    BACK
    - Third Patient Improves from Complete to Incomplete Spinal Cord Injury -

    CAMBRIDGE, Mass. (July 6, 2015) ? InVivo Therapeutics Holdings Corp. (NVIV) today announced a one- month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company?s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury.

    In the time between implantation and the one-month post-injury assessment of the third study patient, the patient improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The patient has regained sacral sensation with improved bladder function. Historically, fewer than 4% of patients with a high thoracic neurologic level of injury convert from AIS A to AIS B in the first month after injury. There were no reported serious adverse events associated with the Neuro-Spinal Scaffold.

    The second patient demonstrated marked improvement in sensory function with partial sensation present five dermatome levels lower on the right side compared to the three-month assessment. This translates to regaining partial sensation from the lower ribs to the hip on the right. The patient continues to make meaningful progress in activities of daily living.

    The Neuro-Spinal Scaffold was implanted in both patients by Dr. Dom Coric of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center (CMC) in Charlotte, NC. The study is being led at CMC by Dr. Coric and Dr. William Bockenek, Chief Medical Officer of Carolinas Rehabilitation and Chairman of the Department of Physical Medicine and Rehabilitation at CMC.

    Dr. Coric said, ?I am very encouraged with the third patient?s neurologic recovery following successful implantation of the investigational Neuro-Spinal Scaffold.? Dr. Bockenek further stated, ?It is exciting and promising when a patient who is classified as a complete spinal cord injury becomes classified as incomplete. This is a relatively unusual occurrence and gives much more potential for further recovery.?

    Mark Perrin, InVivo?s CEO, said, ?We are excited about the neurologic progress that each of our three study patients has made to date. It is particularly noteworthy that two of the patients improved rapidly

    within the first month post-injury from a complete to incomplete spinal cord injury. Patient number one improved from AIS A to AIS C in one month which occurs in fewer than 5% of AIS A patients with T10- T12 injury, and patient number three exhibited improvement AIS A to AIS B which historically is observed in fewer than 4% of patients with a T4 injury. To date, the Neuro-Spinal Scaffold has been successfully implanted in three consecutive patients with no serious adverse events associated with either the scaffold or the surgical procedure. We look forward to continuing to follow these patients and expect to complete enrollment of the remaining two patients in our pilot trial within the coming months.?

    About the Neuro-Spinal Scaffold

    Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

    About InVivo Therapeutics

    InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children?s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company?s investigational Neuro-Spinal Scaffold received the 2015 Becker?s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
    "I'm manic as hell-
    But I'm goin' strong-
    Left my meds on the sink again-
    My head will be racing by lunchtime"

    <----Scott Weiland---->

Similar Threads

  1. Layoffs at Invivo
    By ineedmyelin in forum Cure
    Replies: 1
    Last Post: 07-01-2014, 06:25 AM
  2. Invivo on Fox news
    By ineedmyelin in forum Cure
    Replies: 26
    Last Post: 07-03-2012, 02:44 PM
  3. Invivo Theraputics
    By uAdapt in forum Cure
    Replies: 1
    Last Post: 09-29-2010, 11:37 PM
  4. Any news on InVivo
    By Nicksdad in forum Cure
    Replies: 1
    Last Post: 07-20-2010, 03:23 PM
  5. about InVivo Therapeutics co.
    By manouli in forum Cure
    Replies: 0
    Last Post: 10-31-2008, 12:15 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •